Press release: Future Diagnostics celebrates 25th anniversary
On Friday, May 20, Future Diagnostics will celebrate its 25th anniversary. The company, which develops diagnostic tests on behalf of international biotech companies, will open its doors to invited guests that day. For a snack and a drink, the unveiling of its new logo and a tour of the laboratory in Wijchen.
Future Diagnostics proudly received the re-certification of ISO13485:2016 for the next 3 years. Zero non-conformities were found.
COVID-19 measures at Future Diagnostics
We are committed to keeping you informed of our efforts throughout this pandemic, to make sure that our services to you are as un-affected as possible. The safety and well-being of our employees, their families and customers are our top priority.
National Holidays in The Netherlands
Our company is closed during Easter, Dutch King’s Day, Ascension Day and Pentecost.
Development of Photonic Biosensor Device
Together with the BioCDx consortium, Future Diagnostics has been proudly working on the development of a miniaturized, reliable biosensing system for accurate and highly sensitive detection of protein cancer biomarkers, for the treatment monitoring of cancer disease and the therapeutics response.
At Future Diagnostics, we work on tomorrow’s healthcare projects. That is what makes our work fun and interesting. Especially at this time when healthcare is being tested like this. We take COVID-19 and our responsibility as an employer seriously in this process, while recruiting new colleagues is also important to us. That is why you can also apply at Future Diagnostics during times of COVID-19.
Happy Holiday Season
Last year was extraordinary. We would like to express our sincerest thanks for your continuous support. We cherish the safety and wellbeing of you, our colleagues, our clients and loved ones. We wish you a happy and healthy New Year and we hope to see you again in 2021.
Future Diagnostics Enters Agreement with DIAsource Immunoassays for Free 25OH Vitamin D ELISA product
DIAsource Immunoassays (Louvain-la-Neuve, Belgium), a BioVendor group company, has entered into a strategic agreement with Future Diagnostics (Wijchen, The Netherlands) under which Future Diagnostics will transfer all assets, with the exclusion of IP, related to Free 25OH Vitamin D ELISA product to DIAsource, securing its continued production and sales.